Joseph Newell
Family Medicine · Silsbee, TXNPI 1104277409
Payments from drug & device makers
Across 122 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$616
- Bayer$381
- AstraZeneca$242
- GSK$201
- Lilly USA, LLC$131
- Pfizer$97
- plus $417 from 13 others
What the payments were for
- Food & beverage$2,086100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 44 | $616 |
| Bayer | 20 | $381 |
| AstraZeneca | 10 | $242 |
| GSK | 11 | $201 |
| Lilly USA, LLC | 8 | $131 |
| Pfizer | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Novo Nordisk | 4 | $66 |
| Amgen | 2 | $33 |
| Exact Sciences | 2 | $33 |
| Silk Road Medical, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Novartis | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$106
How this compares
$2,086 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $75,713 |
| EliquisApixaban | 38 | $33,376 |
| OzempicSemaglutide | 20 | $27,722 |
| MounjaroTirzepatide | 13 | $17,668 |
| XareltoRivaroxaban | 19 | $15,053 |
| FarxigaDapagliflozin Propanediol | 13 | $10,638 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,727 |
| LinzessLinaclotide | 13 | $7,411 |
| Novolog FlexpenInsulin Aspart | 17 | $3,898 |
| Ursodiol | 12 | $3,620 |
| Levothyroxine Sodium | 256 | $1,996 |
| Gabapentin | 94 | $1,838 |
| Tramadol Hcl | 100 | $1,353 |
| Ramipril | 156 | $1,308 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $201 | $75,71379 claims |
| PfizerEliquis | $97 | $33,37638 claims |
| Novo NordiskOzempic | $66 | $27,72220 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $242 | $19,36527 claims |
| Lilly USA, LLCMounjaro | $131 | $17,66813 claims |
| AbbVieLinzess | $616 | $7,41113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Silsbee
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.